TABLE 2.

NLRP3 constituents inhibitors.

Inhibitor	Inhibition mechanism	Clinical status	Refs.
Emricasan	Caspase inhibitor	Phase 3	Barreyro et al. (2015), Garcia-Tsao et al. (2020)
β-Hydroxybutyrate	Inhibits K+ efflux; inhibits ASC speck oligomerization	—	Youm et al. (2015)
Andrographolide	NF-κB inhibitor	—	Cabrera et al. (2017)
Compound C	ATP-competitive AMPK inhibitor	—	Wang et al. (2019)
Necrosulfonamide	GSDMD inhibitor	Phase 2	Majdi et al. (2020)
SGM-1019	P2X7 receptor inhibitor	Phase 2	Di Virgilio et al. (2017), Alharthi et al. (2020)